共 42 条
SCFFbxo9 and CK2 direct the cellular response to growth factor withdrawal via Tel2/Tti1 degradation and promote survival in multiple myeloma
被引:83
作者:
Fernandez-Saiz, Vanesa
[1
]
Targosz, Bianca-Sabrina
[1
]
Lemeer, Simone
[2
]
Eichner, Ruth
[1
]
Langer, Christian
[3
]
Bullinger, Lars
[3
]
Reiter, Clemens
[1
]
Slotta-Huspenina, Julia
[4
]
Schroeder, Sonja
[1
]
Knorn, Anna-Maria
[1
]
Kurutz, Julia
[1
]
Peschel, Christian
[1
]
Pagano, Michele
[5
]
Kuster, Bernhard
[2
,6
]
Bassermann, Florian
[1
]
机构:
[1] Tech Univ Munich, Klinikum Rechts Isar, Dept Med 3, D-81675 Munich, Germany
[2] Tech Univ Munich, Dept Prote & Bioanalyt, D-85354 Freising Weihenstephan, Germany
[3] Univ Ulm, Dept Internal Med 3, D-89081 Ulm, Germany
[4] Tech Univ Munich, Klinikum Rechts Isar, Dept Pathol, D-81675 Munich, Germany
[5] NYU, Sch Med, NYU Canc Inst, Dept Pathol, New York, NY 10016 USA
[6] CIPSM, D-85354 Freising Weihenstephan, Germany
关键词:
PROTEIN-KINASE CK2;
FORMALIN-FIXED TISSUES;
MTOR;
INHIBITION;
STABILITY;
COMPLEX;
CANCER;
TEL2;
ATR;
MECHANISM;
D O I:
10.1038/ncb2651
中图分类号:
Q2 [细胞生物学];
学科分类号:
071013 [干细胞生物学];
摘要:
The Tel2 (also known as Telo2) and Tti1 proteins control the cellular abundance of mammalian PIKKs and are integral components of mTORC1 and mTORC2. Here we report that Tel2 and Tti1 are targeted for degradation within mTORC1 by the SCFFbxo9 ubiquitin ligase to adjust mTOR signalling to growth factor availability. This process is primed by CK2, which translocates to the cytoplasm to mediate mTORC1-specific phosphorylation of Tel2/Tti1, subsequent to growth factor deprivation. As a consequence, mTORC1 is inactivated to restrain cell growth and protein translation whereas relief of feedback inhibition activates the PI(3)K/TORC2/Akt pathway to sustain survival. Significantly, primary human multiple myelomas exhibit high levels of Fbxo9. In this setting, PI(3)K/TORC2/Akt signalling and survival of multiple myeloma cells is dependent on Fbxo9 expression. Thus, mTORC1-specific degradation of the Tel2 and Tti1 proteins represents a central mTOR regulatory mechanism with implications in multiple myeloma, both in promoting survival and in providing targets for the specific treatment of multiple myeloma with high levels of Fbxo9 expression.
引用
收藏
页码:72 / U164
页数:32
相关论文

